Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-108 in relapsed/refractory MDS, CMML, and AML
NCT04139434Phase 1Completed
- Sponsor
- Newave Pharmaceutical Inc.
- Start
- Jul 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of lacutoclax in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) (2 arms), sponsored by Newave Pharmaceutical Inc. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 3 more. Started Jul 2020; status: completed.
02
Drugs
lacutoclax
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04139434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04139434.